We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genentech’s Plan To Restrict Avastin Under Scrutiny

Law360 (November 30, 2007, 12:00 AM EST) -- A U.S. senator is investigating Genentech Inc.’s proposed plan to limit the availability of its cancer drug Avastin to certain pharmaceutical compounding firms and pharmacies.

In letters made public Nov. 28, U.S. Senate Special Committee on Aging Chairman Herb Kohl (D-Wisc.) revealed that he has authorized his staff to make inquiries concerning the circumstances surrounding Genentech’s announced partial withdrawal of Avastin from the marketplace.

The letters referenced an Oct. 12 article in the Wall Street Journal which reported that because Medicare is a large purchaser of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.